Allen T J, Hulthen U L, Rumble J R, Jasik M, Cooper M E
Department of Medicine, University of Melbourne, Austin, Australia.
J Diabetes Complications. 1995 Oct-Dec;9(4):318-22. doi: 10.1016/1056-8727(95)80031-9.
The role of angiotensin-converting enzyme (ACE) inhibition with ramipril on mesenteric vascular hypertrophy and urinary albumin excretion was explored in a normotensive model of experimental diabetes. Serial measurements of albuminuria were performed in Sprague-Dawley control, diabetic rats, and diabetic rats treated with ramipril. Over 24 weeks, urinary albumin excretion showed a continuous rise in the untreated diabetic rats. Ramipril prevented the increase in albuminuria over the whole study period. After 6 months, animals were perfused with glutaraldehyde and sacrificed for measurement of mesenteric vessel wall/lumen ratio and kidney weight. Diabetes was associated with increased mesenteric wall/lumen ratio and kidney weight. ACE inhibition, despite no effect on glycemic control, attenuated mesenteric vascular hypertrophy but did not decrease kidney weight. In addition to the well-described renoprotective effects of ACE inhibition in diabetes, this class of agents may have a favorable effect on diabetic vascular disease.
在实验性糖尿病的正常血压模型中，探讨了雷米普利抑制血管紧张素转换酶（ACE）对肠系膜血管肥大和尿白蛋白排泄的作用。对斯普拉格-道利对照大鼠、糖尿病大鼠以及用雷米普利治疗的糖尿病大鼠进行了蛋白尿的系列测量。在24周内，未治疗的糖尿病大鼠尿白蛋白排泄持续增加。雷米普利在整个研究期间阻止了蛋白尿的增加。6个月后，用戊二醛灌注动物并处死，以测量肠系膜血管壁/管腔比值和肾脏重量。糖尿病与肠系膜壁/管腔比值增加和肾脏重量增加有关。ACE抑制尽管对血糖控制无影响，但减轻了肠系膜血管肥大，但未降低肾脏重量。除了ACE抑制在糖尿病中广为人知的肾脏保护作用外，这类药物可能对糖尿病血管疾病有有益作用。
